Ephenidine

Ephenidine
the skeletal formula of ephenidine
Chemical Nomenclature
Common names	Ephenidine
Systematic name	N-Ethyl-1,2diphenylethylamine
Class Membership
Psychoactive class	Dissociative
Chemical class	Diarylethylamine
Routes of Administration
Oral Dosage WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy. Threshold 50 - 60 mg Light 60 - 110 mg Common 110 - 150 mg Strong 150 - 200 mg Heavy 200 mg + Duration Total 5 - 7 hours Onset 10 - 30 minutes

Summary sheet: Ephenidine

Ephenidine (N-Ethyl-1,2diphenylethylamine, NEDPA and EPE) is a dissociative NMDA receptor antagonist and anesthetic drug of the diarylethylamine chemical class. It has similar effects to that of the arylcyclohexylamine and morphinan classes of dissociatives.

This compound induces a state referred to as "dissociative anesthesia" and is used as a recreational drug. Very little is known about this substance, but it has recently become easily accessible through online research chemical vendors where it is being sold as a designer drug. It is illegal in some countries as a structural isomer of the banned opioid drug lefetamine, but has been sold in countries where it is not yet banned.

Chemistry

Ephenidine is a molecule of the diarylethylamine class. It contains a substituted phenethylamine skeleton with an additional phenyl ring bound to R_α. An ethyl chain is bound to the terminal amine R_N of the phenethylamine. Ephenidine is structurally analogous to diphenidine and MXP, but is not a piperidine dissociative. Ephenidine shares a diphenylethylamine skeleton with diphenidine and MXP, but lacks a piperidine substitution.

Pharmacology

Main article: NMDA receptor antagonist

Ephenidine is thought to act as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually this substance's equivalent of the “K-hole.”

This compound induces considerable stimulation at higher doses which suggests that it might function as a serotonin, dopamine and noradrenaline reuptake inhibitor in a similar manner to other dissociatives.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

• Tactile disconnection
• Pain relief
• Spontaneous tactile sensations - The ephenidine "body high" is a soft and pleasurable tingling sensation which is motionless and all-encompassing with no specific location.
• Stimulation - This compound provides stimulating effects at lower doses which are less intense than that of diphenidine or methoxphenidine.
• Tactile suppression - This partially to entirely suppresses one's sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
• Motor control loss - A loss of gross and fine motor control alongside of balance and coordination is prevalent within the ephenidine experience and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless one is experienced) in case of falling over and injuring oneself.
• Perception of decreased weight - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
• Physical autonomy
• Increased heart rate
• Stimulation

Cognitive effects

The general head space of ephenidine is often described as particularly euphoric and clear-headed in comparison to that of DXM and ketamine. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:

• Thought acceleration and deceleration
• Depersonalization
• Derealization
• Consciousness disconnection
• Memory suppression
  • Ego death - This occurs at high dosage.
• Ego inflation - This occurs at low dosage and in a fashion that is less intense to that of mephedrone, methamphetamine or cocaine.
• Motivation enhancement - This occurs at low dosage.
• Information processing suppression
• Time distortion
• Euphoria
• Introspection
• Déjà vu
• Conceptual thinking
• Compulsive redosing
• Anxiety suppression
• Disinhibition
• Amnesia
• Unity and interconnectedness

Visual effects

Suppression

• Visual disconnection - This eventually results in the ephenidine equivalent of the famous "k-hole" or, more specifically, holes, spaces and voids alongside of structures. However, it is worth noting that particularly heavy doses must be consumed to reach the deepest state of this component in comparison to other more classical dissociatives such as ketamine or methoxetamine.
• Visual acuity suppression
• Double vision - This component is prevalent at moderate to heavy dosages and makes reading impossible unless one closes an eye.
• Pattern recognition suppression - This effect generally occurs at higher dosages and makes one unable to recognize and interpret perceivable visual data.
• Frame rate suppression

Distortions

• Drifting (melting, flowing, breathing and morphing) - In comparison to other dissociatives, this effect is more prominent than ketamine, MXE, diphenidine and methoxphenidine. The visual drifting is simplistic, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style.
• Perspective distortions
• Scenery slicing

Geometry

The visual geometry found within ephenidine can be described as very distinct and psychedelic when compared to that of ketamine, MXE, methoxphenidine and diphenidine. It is considerably less detailed than that of DXM. It does not extend beyond level 5 and can be comprehensively described through its variations as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.

Hallucinatory states

At high doses, ephenidine can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics. These effects include:

• Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - In comparison to other dissociatives, this effect can occur at heavy dosages, but is considerably less common than the same effect found within psychedelics and deliriants. It can be comprehensively described through its variations as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.

Auditory effects

• Enhancements
• Suppression
• Distortions
• Hallucinations

Toxicity and harm potential

Main article: Research chemicals § Toxicity and harm potential

The toxicity and long-term health effects of recreational ephenidine use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because ephenidine has very little history of human usage. Anecdotal evidence from people who have tried ephenidine within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of ephenidine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of ephenidine develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Ephenidine presents cross-tolerance with all dissociatives, meaning that after the consumption of ephenidine all dissociatives will have a reduced effect.

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

• Depressants - This combination potentiates the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it. Examples include 1,4-butanediol, 2-methyl-2-butanol, benzodiazepines, GHB, GBL, and opioids.

Legal issues

This legality section is a stub. As such, it likely contains incomplete or wrong information. You can help by expanding it.

• Sweden - Sweden's public health agency suggested that Ephenidine be classified as a hazardous substance on the 1st of June, 2015. Due to that suggestion, Ephenidine became a scheduled substance, in Sweden, as of the 18th of August, 2015.

See also

• Responsible use
• Dissociative
• Diphenidine
• Methoxphenidine
• Methoxetamine

External links

• Ephenidine (Wikipedia)
• Ephenidine (Erowid)
• Ephenidine (TripSit)
• Ephenidine (Bluelight)
• Ephenidine experiences (Erowid)